# Special Issue

# Updates on Breast Cancer Interventional and Diagnostic Imaging

### Message from the Guest Editor

Recent updates on breast cancer screening emphasize the importance of personalized approaches to enhance early detection and treatment outcomes and advances in imaging technologies, such as digital breast tomosynthesis (DBT), MRI, and contrast-enhanced mammography (CEM), have improved the accuracy of tumor detection, especially in women with dense breast tissue. Genetic screening and risk assessment models are increasingly utilized to identify individuals at higher risk, allowing for tailored screening strategies, and the integration of artificial intelligence (AI) in mammography interpretation has shown promise in reducing false positives and improving diagnostic efficiency. Additionally, updated guidelines suggest more nuanced recommendations regarding the age and frequency of screening, balancing the benefits of early detection with the risks of overdiagnosis and overtreatment. Ongoing research and clinical trials continue to refine these approaches, aiming to optimize screening protocols and outcomes for diverse populations.

#### **Guest Editor**

Dr. Jacopo Nori

Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

### Deadline for manuscript submissions

31 May 2025



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/205911

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/ cancers





# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

